Novel Endogenous Angiogenesis Inhibitors and Their Therapeutic Potential

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2015 Sep 15

PMID 26364800

Citations 34

Authors

Nithya Rao

Yu Fei Lee

Ruowen Ge

Affiliations

Soon will be listed here.

Abstract

Angiogenesis, the formation of new blood vessels from the pre-existing vasculature is essential for embryonic development and tissue homeostasis. It also plays critical roles in diseases such as cancer and retinopathy. A delicate balance between pro- and anti-angiogenic factors ensures normal physiological homeostasis. Endogenous angiogenesis inhibitors are proteins or protein fragments that are formed in the body and have the ability to limit angiogenesis. Many endogenous angiogenesis inhibitors have been discovered, and the list continues to grow. Endogenous protein/peptide inhibitors are relatively less toxic, better tolerated and have a lower risk of drug resistance, which makes them attractive as drug candidates. In this review, we highlight ten novel endogenous protein angiogenesis inhibitors discovered within the last five years, including ISM1, FKBPL, CHIP, ARHGAP18, MMRN2, SOCS3, TAp73, ZNF24, GPR56 and JWA. Although some of these proteins have been well characterized for other biological functions, we focus on their new and specific roles in angiogenesis inhibition and discuss their potential for therapeutic application.

Citing Articles

Adipokine isthmin-1 is a potential predictor of abnormal urine Na excretion and insulin resistance for primary hypertension.

Deng C, Zhou X, Zhang L, You Q, Liu C, Zhang Y BMC Cardiovasc Disord. 2025; 25(1):136.

PMID: 40011820 PMC: 11863623. DOI: 10.1186/s12872-025-04585-z.

New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases.

van Noorden C, Yetkin-Arik B, Serrano Martinez P, Bakker N, van Breest Smallenburg M, Schlingemann R J Histochem Cytochem. 2024; 72(5):329-352.

PMID: 38733294 PMC: 11107438. DOI: 10.1369/00221554241249515.

In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma.

Cardama G, Bucci P, Lemos J, Llavona C, Benavente M, Hellmen E Animals (Basel). 2023; 13(15).

PMID: 37570315 PMC: 10417262. DOI: 10.3390/ani13152507.

Angiogenic signaling pathways and anti-angiogenic therapy for cancer.

Liu Z, Chen H, Zheng L, Sun L, Shi L Signal Transduct Target Ther. 2023; 8(1):198.

PMID: 37169756 PMC: 10175505. DOI: 10.1038/s41392-023-01460-1.

Primary tumor-derived systemic nANGPTL4 inhibits metastasis.

Hubers C, Abdul Pari A, Grieshober D, Petkov M, Schmidt A, Messmer T J Exp Med. 2022; 220(1).

PMID: 36269299 PMC: 9595206. DOI: 10.1084/jem.20202595.

References

Verheul H, Pinedo H . Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007; 7(6):475-85. DOI: 10.1038/nrc2152. View

Harper J, Yan L, Loureiro R, Wu I, Fang J, DAmore P . Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res. 2007; 67(18):8736-41. DOI: 10.1158/0008-5472.CAN-07-1617. View

Wang J, Liu Y, Hande M, Wong A, Jin Y, Yin Y . TAp73 is a downstream target of p53 in controlling the cellular defense against stress. J Biol Chem. 2007; 282(40):29152-62. DOI: 10.1074/jbc.M703408200. View

Khalfallah O, Faucon-Biguet N, Nardelli J, Meloni R, Mallet J . Expression of the transcription factor Zfp191 during embryonic development in the mouse. Gene Expr Patterns. 2007; 8(3):148-54. DOI: 10.1016/j.gep.2007.11.002. View

Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L . Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A. 2002; 99(20):12847-52. PMC: 130548. DOI: 10.1073/pnas.202365899. View

Thomas J, Arzoomanian R, Alberti D, Marnocha R, Lee F, Friedl A . Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003; 21(2):223-31. DOI: 10.1200/JCO.2003.12.120. View

Benard J, Douc-Rasy S, Ahomadegbe J . TP53 family members and human cancers. Hum Mutat. 2003; 21(3):182-91. DOI: 10.1002/humu.10172. View

Nozell S, Wu Y, McNaughton K, Liu G, Willis A, Paik J . Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene. 2003; 22(28):4333-47. DOI: 10.1038/sj.onc.1206470. View

Westphal J . Technology evaluation: ABT-510, Abbott. Curr Opin Mol Ther. 2004; 6(4):451-7. View

10.

Klingenberg M . The ADP and ATP transport in mitochondria and its carrier. Biochim Biophys Acta. 2008; 1778(10):1978-2021. DOI: 10.1016/j.bbamem.2008.04.011. View

11.

Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung C . TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008; 22(19):2677-91. PMC: 2559903. DOI: 10.1101/gad.1695308. View

12.

Li X, Liu Q, Liu S, Zhang J, Zhang Y . New member of the guanosine triphosphatase activating protein family in the human epididymis. Acta Biochim Biophys Sin (Shanghai). 2008; 40(10):855-63. View

13.

McKeen H, McAlpine K, Valentine A, Quinn D, McClelland K, Byrne C . A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology. 2008; 149(11):5724-34. DOI: 10.1210/en.2008-0168. View

14.

Zhang J, Cao R, Zhang Y, Jia T, Cao Y, Wahlberg E . Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 2008; 23(1):153-63. DOI: 10.1096/fj.08-113860. View

15.

Crabb S, Patsios D, Sauerbrei E, Ellis P, Arnold A, Goss G . Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2008; 27(3):404-10. DOI: 10.1200/JCO.2008.16.2545. View

16.

Schwarze S, Rangnekar V . Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biol Ther. 2009; 9(2):153-5. DOI: 10.4161/cbt.9.2.10760. View

17.

Stahl A, Connor K, Sapieha P, Chen J, Dennison R, Krah N . The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010; 51(6):2813-26. PMC: 2891451. DOI: 10.1167/iovs.10-5176. View

18.

Li J, Chen X, Liu Y, Ding L, Qiu L, Hu Z . The transcriptional repression of platelet-derived growth factor receptor-beta by the zinc finger transcription factor ZNF24. Biochem Biophys Res Commun. 2010; 397(2):318-22. DOI: 10.1016/j.bbrc.2010.05.110. View

19.

Ying M, Li D, Yang L, Wang M, Wang N, Chen Y . Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol. 2010; 136(10):1617-26. DOI: 10.1007/s00432-010-0819-6. View

20.

Noh Y, Matsuda K, Hong Y, Kunstfeld R, Riccardi L, Koch M . An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol. 2003; 121(6):1536-43. DOI: 10.1046/j.1523-1747.2003.12643.x. View